Syngen Biotech Co.,Ltd. (TPEX:8279)

Taiwan · Delayed Price · Currency is TWD

97.00

-0.90 (-0.92%)

Jun 18, 2026, 1:30 PM CST

-27.07% (1Y)

Market Cap	2.63B -31.0%
Revenue (ttm)	2.07B +1.7%
Net Income	243.83M +0.9%
EPS	8.76 -1.6%
Shares Out	27.10M
PE Ratio	11.07
Forward PE	n/a
Dividend	5.00 (5.15%)
Ex-Dividend Date	Jun 25, 2026

Volume	9,404
Open	96.80
Previous Close	97.90
Day's Range	96.00 - 97.10
52-Week Range	94.30 - 141.00
Beta	0.16
Analysts	Buy
Price Target	170.00 (+75.26%)
Earnings Date	Jul 27, 2026

About Syngen Biotech

Syngen Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan, China, and internationally. The company offers dietary supplements; supplement contract manufacturing services in the form of sachets, liquids, tablets, cup package capsules, jellies, aluminum and glass bottles, and gummies; science-based and bio active pharmaceutical ingredient... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1988

Employees 247

Stock Exchange Taipei Exchange

Ticker Symbol 8279

Full Company Profile

Financial Performance

In 2025, Syngen Biotech's revenue was 2.14 billion, an increase of 6.10% compared to the previous year's 2.01 billion. Earnings were 271.59 million, an increase of 13.07%.

Financial Statements